CHMP issues positive opinion Keytruda + chemo as first-line treatment for metastatic biliary tract cancer

Phase III trial of subcutaneous pembrolizumab with berahyaluronidase alfa meets primary endpoints

Merck announced positive topline results from the pivotal phase III MK-3475A-D77 trial.

November 22, 2024

Keytruda improves outcomes in soft tissue sarcoma

Addition of the immunotherapy drug pembrolizumab (Keytruda) to standard of care for patients with advanced soft tissue sarcoma of the limb significantly improved disease-free survival, according to the results of the SU2C-SARC032 clinical trial led by researchers from the University of Pittsburgh, UPMC, Duke University, and Princess Margaret Cancer Centre.

November 15, 2024

Vol.50 No.43

Clinical Roundup

Phase I clinical trial of Keytruda + Lymphir for recurrent solid tumors yields positive preliminary results

Promising preliminary results from an ongoing investigator-initiated phase I clinical trial evaluating the safety and efficacy of a combined regimen of Keytrua (pembrolizumab) and Lymphir (denileukin diftitox-cxdl or E7777) in patients with recurrent solid tumors were announced.

November 15, 2024

Vol.50 No.43

Drugs & Targets

EC approves Keytruda combinations for endometrial carcinoma indication, FIGO 2014 stage III-IVA locally advanced cervical cancer

The European Commission has approved two new indications for Keytruda (pembrolizumab), an anti-PD-1 therapy, in gynecologic cancers.

October 25, 2024

Vol.50 No.40

Drugs & Targets

EMA CHMP grants positive opinion of Korjuny for malignant ascites

The European Medicines Agency Committee for Medicinal Products for Human Use has adopted a positive opinion recommending the approval of trifunctional anti-CD3 x anti-EpCAM antibody Korjuny (catumaxomab) for the intraperitoneal treatment of malignant ascites in adults with EpCAM-positive carcinomas who are not eligible for further systemic anticancer therapy.

October 25, 2024

Vol.50 No.40

Drugs & Targets

EMA CHMP issues positive opinions for Tevimbra for gastric or GEJ adenocarcinoma and ESCC

The European Medicine Agency Committee for Medicinal Products for Human Use issued positive opinions recommending an extended authorization for Tevimbra (tislelizumab) in gastric or gastroesophageal junction adenocarcinoma and esophageal squamous cell carcinoma.

October 25, 2024

Vol.50 No.40

CHMP issues positive opinion Keytruda + chemo as first-line treatment for metastatic biliary tract cancer

YOU MAY BE INTERESTED IN

Phase III trial of subcutaneous pembrolizumab with berahyaluronidase alfa meets primary endpoints

Keytruda improves outcomes in soft tissue sarcoma

Phase I clinical trial of Keytruda + Lymphir for recurrent solid tumors yields positive preliminary results

EC approves Keytruda combinations for endometrial carcinoma indication, FIGO 2014 stage III-IVA locally advanced cervical cancer

EMA CHMP grants positive opinion of Korjuny for malignant ascites

EMA CHMP issues positive opinions for Tevimbra for gastric or GEJ adenocarcinoma and ESCC

Renew today!

Subscriber content

Never miss an issue!

Login